ensitrelvir
Selected indexed studies
- Ensitrelvir Fumaric Acid: First Approval. (Drugs, 2024) [PMID:38795314]
- Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial. (JAMA Netw Open, 2024) [PMID:38335000]
- Ensitrelvir in Hospitalized Patients with SARS-CoV-2 During the Omicron Epidemic: A Single-Center Observational Study. (Infect Dis Ther, 2025) [PMID:40252170]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Ensitrelvir Fumaric Acid: First Approval. (2024) pubmed
- Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial. (2024) pubmed
- Ensitrelvir in Hospitalized Patients with SARS-CoV-2 During the Omicron Epidemic: A Single-Center Observational Study. (2025) pubmed
- Ensitrelvir as a novel treatment option for mild-to-moderate COVID-19: a narrative literature review. (2025) pubmed
- Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial. (2025) pubmed
- Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally. (2023) pubmed
- Ensitrelvir as a potential treatment for COVID-19. (2022) pubmed
- Efficacy and safety of Ensitrelvir in asymptomatic or mild to moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials. (2025) pubmed
- Ensitrelvir treatment-emergent amino acid substitutions in SARS-CoV-2 3CL(pro) detected in the SCORPIO-SR phase 3 trial. (2025) pubmed
- Ensitrelvir in patients with SARS-CoV-2: A retrospective chart review. (2024) pubmed